Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

EAU 2026: Updates in NMIBC

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer